WallStreetZenWallStreetZen

NYSE: PHR
Phreesia Inc Stock

$17.64-0.51 (-2.81%)
Updated Sep 26, 2023
PHR Price
$17.64
Fair Value Price
N/A
Market Cap
$973.88M
52 Week Low
$17.44
52 Week High
$40.00
P/E
-6.17x
P/B
3.94x
P/S
5.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$319.36M
Earnings
-$152.49M
Gross Margin
63.5%
Operating Margin
-48.43%
Profit Margin
-47.7%
Debt to Equity
0.38
Operating Cash Flow
-$60M
Beta
1.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PHR Overview

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform also provides a registration solution to automate patient self-registration; patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and life sciences, pharmaceutical, medical device, and biotechnology companies. Phreesia, Inc. has a strategic alliance agreement with Allscripts Healthcare, LLC. The company was founded in 2005 and is headquartered in New York, New York.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PHR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHR is poor value based on its book value relative to its share price (3.94x), compared to the US Health Information Services industry average (3.07x)
P/B vs Industry Valuation
PHR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHR due diligence checks available for Premium users.

Be the first to know about important PHR news, forecast changes, insider trades & much more!

PHR News

Valuation

PHR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.17x
Industry
55.14x
Market
14.06x

PHR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.94x
Industry
3.07x
PHR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PHR's financial health

Profit margin

Revenue
$85.8M
Net Income
-$36.8M
Profit Margin
-42.8%
PHR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PHR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$340.4M
Liabilities
$93.4M
Debt to equity
0.38
PHR's short-term assets ($219.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHR's short-term assets ($219.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.3M
Investing
-$9.7M
Financing
-$3.0M
PHR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PHR vs Health Information Service Stocks

TickerMarket Cap1d %P/EP/B
PHR$973.88M-2.81%-6.17x3.94x
AGTI$896.79M-2.50%221.33x0.94x
NRC$1.11B-1.31%38.10x14.33x
MPLN$1.12B-2.27%-1.64x0.63x
SLP$806.24M-0.54%77.81x4.76x

Phreesia Stock FAQ

What is Phreesia's quote symbol?

(NYSE: PHR) Phreesia trades on the NYSE under the ticker symbol PHR. Phreesia stock quotes can also be displayed as NYSE: PHR.

If you're new to stock investing, here's how to buy Phreesia stock.

What is the 52 week high and low for Phreesia (NYSE: PHR)?

(NYSE: PHR) Phreesia's 52-week high was $40.00, and its 52-week low was $17.44. It is currently -55.9% from its 52-week high and 1.15% from its 52-week low.

How much is Phreesia stock worth today?

(NYSE: PHR) Phreesia currently has 55,208,674 outstanding shares. With Phreesia stock trading at $17.64 per share, the total value of Phreesia stock (market capitalization) is $973.88M.

Phreesia stock was originally listed at a price of $25.08 in Jul 18, 2019. If you had invested in Phreesia stock at $25.08, your return over the last 4 years would have been -29.67%, for an annualized return of -8.42% (not including any dividends or dividend reinvestments).

How much is Phreesia's stock price per share?

(NYSE: PHR) Phreesia stock price per share is $17.64 today (as of Sep 26, 2023).

What is Phreesia's Market Cap?

(NYSE: PHR) Phreesia's market cap is $973.88M, as of Sep 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Phreesia's market cap is calculated by multiplying PHR's current stock price of $17.64 by PHR's total outstanding shares of 55,208,674.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.